Theratechnologies Lowers FY2024 Sales Guidance from $87.00M-90.00M to $83.00M-85.00M, Est $84.044M
Portfolio Pulse from Benzinga Newsdesk
Theratechnologies has revised its FY2024 sales guidance downward from $87-90 million to $83-85 million, aligning closely with the estimated $84.044 million.
October 10, 2024 | 11:36 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Theratechnologies has reduced its FY2024 sales guidance to $83-85 million from the previous $87-90 million range, which is close to the estimated $84.044 million.
The downward revision in sales guidance suggests potential challenges in achieving previous sales targets, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100